The NIH/NHLBI/HEMATOLOGY BRANCH have signed an agreement with Vascarta, Inc to conduct a Phase 1 clinical trial of VAS-101 (Vasceptor®), a topical curcumin gel designed to reduce pain and inflammation in sickle cell disease (SCD). The trial, led by Dr. Swee Lay Thein at NIH Clinical Center (CC), will assess safety, tolerability, and effects on inflammation and red blood cell health. VAS-101 uses patented transdermal technology to deliver curcumin directly into the bloodstream, stabilizing red blood cells and reducing oxidative stress. Preclinical studies suggest it may improve tissue oxygenation and pain management, key unmet needs in SCD.

At OxyDial, we’re excited by approaches like VAS-101 that could offer safer pain relief for SCD patients. If successful, this could complement existing therapies by addressing chronic pain without the risks of opioids or complex dosing.

Read more: https://www.prnewswire.com/news-releases/national-heart-lung-and-blood-institute–national-institutes-of-health-signs-clinical-trial-agreement-with-vascarta-inc-to-perform-phase-1-clinical-study-of-vas-101-in-sickle-cell-disease-302498504.html

#SickleCellDisease #SCD #PainManagement #Curcumin #NonOpioid #Vascarta #VAS101 #NHLBI #NIH #Hematology